Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

EN
ESG Practice and Honor
Home  >  ESG  >  ESG Practice and Honor
Our Performance
  • 67.9 %
    The proportion of innovative drugs and collaborative products revenue in 2023
  • 50 %
    Percentage of female directors reached 50%
  • 25.96 %
    Progress of greenhouse gas emission reduction targets: The emissions of greenhouse gas per unit revenue 2023 (scope I and scope II) reduced by 25.96% than that in 2021
  • 85 % +
    Employee satisfaction rate of 85.5%
  • 92523 person-times
    Hansoh Pharma provided quality related trainingfor a total of 92,523 person-times
  • 28.17 %
    Progress of emission reduction of exhaust pollutants: Total emissions of VOCs in exhaust reduced by 28.17% than that in 2021
  • 100 %
    100% approval rate for product certification checks and customer audits
  • 37
    As of the end of 2023,the number of drugs had entered 37 low- and middle-income countries and regions
ESG Recognitions and Awards
  • MSCI ESG rating scored AA
  • Included in the “S&P Global Sustainability Yearbook (China) 2024”,ranking in the Top 1% for its S&P Global CSA Score(69)in 2023
  • Included in the “S&P Global Sustainability Yearbook 2024”, outperformed other Chinese pharmaceutical companies in terms of CSA Score (69) in 2023
  • Included in the first “Sustainability Yearbook (China)” published by S&P Global, ranking in the Top 1% for its S&P Global ESG score and gained recognition as an “Industry Mover”.
  • Included in the S&P GlobalSustainability Yearbook 2023, the only pharmaceuticalcompanv in China Mainland to be selected
  • The Asset ESG Corporate Awards 2023—GoldAward
  • The Best Industrial Enterprise of Pharmaceutical R&D Product Line in China
  • AAA Credit Rating of Pharmaceutical Industry Enterprises
  • Typical Case of National Intellectual Property Right Demonstration Enterprises
  • Jiangsu Science and Technology Innovation and Development Award
  • ESG Leading Enterprise Awards 2022 organized by Bloomberg Businessweek/Chinese Edition
  • S&P CSA score is significantly improved
  • Named to HRoot's "Excellent Employers in Greater China 2022" List
  • Named to "ESG Competence of China's Listed Pharmaceutical Companies 2022" List
  • Named to "Excellent CSR Programs of China's Pharmaceutical Companies" List
  • Named to "Good CSR Performers in Pudong New Area" List
  • Changzhou Hansoh Pharmaceutical has obtained its first ISO 50001 Energy Management System certification
  • Hansoh Pharma's all production sites obtained the Energy and Environmental Management Systems certification
  • 2020 ESG report won “AA” rating by International Forum on Social Responsibilities of Industrial and Information Enterprises